Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D03QCW
|
||||
Former ID |
DAP001280
|
||||
Drug Name |
Interferon alfa-n1
|
||||
Synonyms |
Alfa-Interferon; Well-feron; Interferon alfa-n1 (USAN); Well-feron (TN)
|
||||
Therapeutic Class |
Antiviral Agents
|
||||
Formula |
C860H1353N227O255S9
|
||||
CAS Number |
CAS 74899-72-2
|
||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
L03AB06
|
||||
Target and Pathway | |||||
Target(s) | Interferon-alpha/beta receptor | Target Info | Binder | [535821], [538052], [538094] | |
References | |||||
Ref 535821 | The clinical application of the interferons: a review. NSW Therapeutic Assessment Group. Med J Aust. 1992 Jun 15;156(12):869-72. | ||||
Ref 538052 | Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology. 1997 Sep;26(3 Suppl 1):96S-100S. | ||||
Ref 538094 | Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.